PIV3
MCID: PRN029
MIFTS: 31

Parainfluenza Virus Type 3 (PIV3) malady

Category: Rare diseases

Aliases & Classifications for Parainfluenza Virus Type 3

About this section

Aliases & Descriptions for Parainfluenza Virus Type 3:

Name: Parainfluenza Virus Type 3 48
Human Parainfluenza Virus Type 3 48
 
Piv3 48

Classifications:



Summaries for Parainfluenza Virus Type 3

About this section
NIH Rare Diseases:48 Parainfluenza virus type 3 is one of a group of common viruses known as human parainfluenza viruses (hpiv) that cause a variety of respiratory illnesses. symptoms usually develop between 2 and 7 days from the time of exposure and typically resolve in 7-10 days. symptoms may include fever, runny nose, and cough. hpiv-3 can also cause bronchiolitis, bronchitis, and pneumonia. infants and young children are particularly susceptible to hpiv-3 infections, though older adults and those with a weakened immune system are also at risk for complications. hpivs are usually spread from an infected person to others through coughing, sneezing, and/or touching. there is currently no vaccine to protect against parainfluenza virus infections. most hpiv infections resolve on their own and do not require special treatment, though medical intervention may be necessary for severe breathing problems. most adults have antibodies against parainfluenza but can get repeat infections. last updated: 8/30/2016

MalaCards based summary: Parainfluenza Virus Type 3, also known as human parainfluenza virus type 3, is related to fetal parainfluenza virus type 3 syndrome and pneumonia. An important gene associated with Parainfluenza Virus Type 3 is NEU1 (Neuraminidase 1), and among its related pathways is Type II interferon signaling (IFNG). Affiliated tissues include lung, t cells and testes, and related mouse phenotypes are Decreased human parainfluenza virus type 3 (HPIV3) infection and Decreased lymphocytic choriomeningitis virus (LCMV) infection.

Related Diseases for Parainfluenza Virus Type 3

About this section

Graphical network of the top 20 diseases related to Parainfluenza Virus Type 3:



Diseases related to parainfluenza virus type 3

Symptoms & Phenotypes for Parainfluenza Virus Type 3

About this section

GenomeRNAi Phenotypes related to Parainfluenza Virus Type 3 according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00241-A-49.8COPA, DCAF13
2GR00241-A-39.8COPA, DCAF13
3GR00241-A-19.1COPA, DCAF13

Drugs & Therapeutics for Parainfluenza Virus Type 3

About this section

Drugs for Parainfluenza Virus Type 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 13)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Ergocalciferolapproved, nutraceuticalPhase 3128150-14-65280793
Synonyms:
'Ergosterol irradiated'
(+)-Vitamin D2
(3-beta,5Z,7E,22E)-9,10-Secoergosta-5,7,10,(19),22-tetraen-3-ol
(3S,5Z,7E,14xi,17alpha,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3S,5Z,7E,22E)-9,10-secoergosta-5,7,10,22-tetraen-3-ol
(3beta,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(3beta,5Z,7e,22e)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
(5E,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Seco-5,7,10(19),22-ergostatetraen-3-ol
(5Z,7e,22e)-(3S)-9,10-Secoergosta-5,7,10(19),22-tetraen-3-ol
22-Tetraen 3beta 9,10,Secoergosta-5,7,10(19)-ol
31316-19-5
4-Methylene-3-[2-[tetrahydro-7a-methyl-1-(1,4,5-trimethyl-2-hexenyl)-4(3aH)-indanylidene]ethylidene]-Cyclohexanol
47768_SUPELCO
50-14-6
7489-18-1
7E677DC1-E1C4-4FC5-8F4A-BCE1857F7E87
8017-28-5
9,10,Secoergosta-5,7,10(19),22-tetraen 3.beta.-ol
9,10-Seco(5Z,7E,22E)-5,7,10(19),22-ergostatetraen-3-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3-beta-ol
9,10-Secoergosta-5,7,10(19),22-tetraen-3b-ol
95220_FLUKA
95220_SIGMA
AC-1355
AC1L1FIE
AC1NQXLH
AC1NS4DE
AC1NS9GI
AC1NSSVD
AC1NWAM3
AC1O5EDK
AC1O6WAM
ACon1_002187
Activated ergosterol
BPBio1_000418
BSPBio_000380
BSPBio_001974
Buco-D
C05441
C28H44O
CALCIFEROL IN A GELATIN MATRIX
CALCIFEROL, U.S.P.
CHEBI:28934
CHEMBL1536
CID11003810
CID3249
CID5280793
CID5315257
CID5353610
CID5356615
CID5702050
CID6432478
CID6536972
Calciferol
Calciferol (TN)
Calciferol (vitamin D2)
Calciferolum
Calciferon 2
Condacaps
Condocaps
Condol
Crtron
Crystallina
D-Arthin
D-Tracetten
D00187
DB00153
Daral
Davitamon D
Davitin
De-rat concentrate
Decaps
Dee-Osterol
Dee-Ron
Dee-Ronal
Dee-Roual
Deltalin
Deratol
Detalup
Diactol
Divit urto
Doral
Drisdol
Drisdol (TN)
E5750_SIGMA
EINECS 200-014-9
Ercalciol
Ergocalciferol
Ergocalciferol (D2)
Ergocalciferol (JP15/USP)
Ergocalciferol [INN:BAN:JAN]
Ergocalciferol oil
Ergocalciferol: Vitamin D
 
Ergocalciferolo
Ergocalciferolo [DCIT]
Ergocalciferols
Ergocalciferolum
Ergocalciferolum [INN-Latin]
Ergorone
Ergosterol activated
Ergosterol irradiated
Ergosterol, irradiated
Ertron
Fortodyl
Geltabs
Geltabs Vitamin D
HMS1920K20
HMS2091B19
HMS502I07
HSDB 819
Haliver
Hi-Deratol
Hyperkil
I05-0022
IDI1_000805
Infron
Irradiated ergosta-5,7,22-trien-3-beta-ol
Irradiated ergosta-5,7,22-trien-3.beta.-ol
Irradiated ergosta-5,7,22-trien-3beta-ol
Irradiated ergosterol
LMST03010001
LMST03010014
LS-3228
MEGxm0_000466
MLS001332467
MLS001332468
Metadee
Mina D2
MolPort-001-740-057
MolPort-001-793-930
MolPort-002-526-645
MolPort-003-666-178
MolPort-006-822-629
Mulsiferol
Mykostin
NCGC00142497-01
NCGC00179579-01
NCGC00179579-02
NSC 62792
NSC62792
Novovitamin-D
Oleovitamin D
Oleovitamin D, Synthetic
Oleovitamin D2
Osteil
Ostelin
Prestwick3_000420
Prestwick_554
Radiostol
Radstein
Radsterin
Rodine C
Rodinec
SMR000857106
SPECTRUM1500276
ST057150
STOCK1N-53397
Shock-ferol
Shock-ferol sterogyl
Sorex C.R
Sorex C.R.
Spectrum5_000666
Sterogyl
Synthetic Vitamin D
UNII-VS041H42XC
Uvesterol D
Uvesterol-D
VITAMIN D2
VITAMIN D2 WATER DISPERSABLE U.S.P.
VITAMIN_D2
Vigantol
Vio D
Vio-D
Viostdrol
Viosterol
Viosterol in Oil
Vitamin D2
Vitamin- D2
Vitamin-?D2
Vitamina D2
Vitavel-D
WLN: L56 FYTJ A1 BY1&1U1Y1&Y1&1 FU2U- BL6YYTJ AU1 DQ
ZINC04474571
ZINC04629876
beta-Ol
bmse000510
component of Geltabs Vitamin D
delta-Arthin
delta-Tracetten
ergocalciferol
vitamin d-2
2
Cholecalciferolapproved, nutraceuticalPhase 387567-97-06221, 10883523, 5280795
Synonyms:
()-Vitamin D3
(+)-Vitamin D3
(+)-vitamin D3
(1S,3Z)-3-[(2e)-2-[(1R,3AR,7as)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol
(3S,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(3beta,Z,7E)-9,10-Secocholesta-5,7,10(19)-trien-3-ol
(3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-trien-3-ol
(5E,7E)-9,10-Secocholesta-5,7,10-trien-3-ol
(5Z,7E)-(3S)-9,10-seco-5,7,10(19)-cholestatrien-3-ol
(5Z,7E)-(3S)-9,10-secocholesta-5,7,10(19)-trien-3-ol
1406-16-2
25(OH)D
3-beta,Z,7E-9,10-Secocholestr-5,7,10(19)-trien-3-ol
47763_SUPELCO
57651-82-8
67-97-0
7-Dehydrocholesterol activated
7-Dehydrocholesterol, Activated
7-Dehydrocholesterol, irradiated
7-Dehydrocholestrol, activated
8024-19-9
8050-67-7
89193_FLUKA
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3-ol
9,10-Seco(5Z,7E)-5,7,10(19)-cholestatrien-3beta-ol
9,10-Secocholesta-5(Z),7(E),10(19)-trien-3(.beta.)-ol
9,10-Secocholesta-5,7,10(19)-trien-3-beta-ol
9,10-Secocholesta-5,7,10(19)-trien-3-ol
9,10-Secocholesta-5,7,10-trien-3-ol
AB1002422
AC-11697
AC1L1ECK
AC1L1M23
AC1LU7IZ
AC1NQXLN
AC1NR2UO
AC1NR2UR
AC1NR2UU
AC1NS4AJ
AC1NSHJX
AC1O5EOF
AC1O7GAV
AC1O7GQ3
AC1O8FEU
AC1O8PWJ
AC1OF2GI
AC1OF2GL
AC1OIEW5
AC1OIEWB
ACon1_001997
Activated 7-dehydrocholesterol
Arachitol
BPBio1_000460
BSPBio_000418
BSPBio_002408
Bio-0845
C05443
C1357_SIAL
C27H44O
C9756_SIGMA
C9774_SIAL
CAS-67-97-0
CC
CCRIS 5813
CCRIS 6286
CHEBI:283119
CHEBI:28940
CHEMBL1042
CHEMBL432780
CID10000117
CID10045875
CID10340013
CID10883523
CID10894379
CID11014566
CID11025493
CID11058152
CID11463269
CID1548921
CID2735
CID5280795
CID5283710
CID5283711
CID5283712
CID5353527
CID5363362
CID6221
CID6432644
CID6604201
CID6604662
CID6708595
CID6713938
CID6992015
CID6992016
CID7067439
CID7067440
CID7251172
CID7251174
CID9821465
Calciol
Cholecalciferol
Cholecalciferol (D3)
Cholecalciferol (JP15/USP)
Cholecalciferol D3
Cholecalciferol [USAN:BAN:JAN]
Cholecalciferol, D3
Cholecalciferolum
Colecalciferol
 
Colecalciferol (INN)
Colecalciferolo
Colecalciferolo [DCIT]
Colecalciferolum
Colecalciferolum [INN-Latin]
Colecalcipherol
D00188
D3-Vicotrat
D3-Vigantol
DB00169
Delsterol
Delta-D
Delta-D (TN)
Deparal
Devaron
DivK1c_006276
Duphafral D3 1000
EINECS 200-673-2
EINECS 215-797-2
EPA Pesticide Chemical Code 202901
Ebivit
FeraCol
Granuvit D3
HMS1569E20
HMS2092M12
HSDB 820
I05-0041
Irradiated 7-dehydrocholesterol
KBio1_001220
KBio2_001643
KBio2_004211
KBio2_006779
KBio3_001628
KBioGR_001602
KBioSS_001643
LMST03020001
LMST03020219
LMST03020220
LMST03020221
LS-1570
LS-825
LT00244775
MEGxm0_000458
Micro-dee
MolPort-001-740-051
MolPort-001-785-972
MolPort-003-666-021
MolPort-004-946-964
NCGC00016301-01
NCGC00017328-01
NCGC00091072-01
NCGC00142511-01
NCGC00159331-02
NCGC00159331-04
NCGC00178668-01
NCGC00179565-01
NCGC00179565-02
NEO Dohyfral D3
NSC 375571
NSC-375571
NSC375571
Oleovitamin D3
Prestwick0_000429
Prestwick1_000429
Prestwick2_000429
Prestwick3_000429
Prestwick_63
Provitamine
Provitina
Quintox
Rampage
Ricketon
SMP1_000068
SPBio_001298
SPBio_002357
SR-05000001559
SR-05000001559-3
ST057172
SpecPlus_000180
Spectrum2_001369
Spectrum3_000764
Spectrum4_001201
Spectrum_001163
TNP00266
Trivitan
UNII-1C6V77QF41
UPCMLD-DP152
UPCMLD-DP152:001
VITAMIN D
VITAMIN D3 POWDER
VITAMIN_D3
Vi-De3
Vi-de-3-hydrosol
VidDe-3-hydrosol
Videkhol
Vigantol
Vigorsan
Vitamin D-3
Vitamin D3
Vitamin D3 emulsifiable
Vitinc Dan-Dee-3
ZINC04474460
ZINC04492874
ZINC04492875
ZINC04492876
ZINC04492878
bmse000507
cholecalciferol
colecalciferolum
vitamin d-3
3vitamin dPhase 31724
4VitaminsPhase 35282
5Bone Density Conservation AgentsPhase 33376
6Trace ElementsPhase 36001
7ErgocalciferolsPhase 31281
8MicronutrientsPhase 36001
9CalciferolNutraceuticalPhase 31383
10Vitamin D2NutraceuticalPhase 31281
11VaccinesPhase 1, Phase 26611
12Glutamic AcidNutraceuticalPhase 1, Phase 2228
13KrestinPhase 1210

Interventional clinical trials:

(show all 15)
idNameStatusNCT IDPhase
1Maternal Vitamin D for Acute Respiratory Infections in InfancyCompletedNCT02388516Phase 3
2A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old InfantsCompletedNCT00686075Phase 1, Phase 2
3A Phase 1/2A Study to Evaluate the Safety, Immunogenicity, and Shedding of MEDI-560 in Infants 1 to < 12 Months of AgeTerminatedNCT00508651Phase 1, Phase 2
4Evaluating the Safety of and Immune Response to a Human Parainfluenza Virus Type 3 Ebola Virus Vaccine (HPIV3-EbovZ GP) in Healthy AdultsCompletedNCT02564575Phase 1
5Study to Evaluate the Safety of MEDI-534 Vaccine Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3) in Healthy ChildrenCompletedNCT00345670Phase 1
6Evaluating the Safety and Immunogenicity of a Human Parainfluenza Type 3 (HPIV3) Virus Vaccine in Infants and ChildrenCompletedNCT01254175Phase 1
7Safety of and Immune Response to a Cow/Human Parainfluenza Virus Vaccine (rB/HPIV3) in Healthy Infants, Children, and AdultsCompletedNCT00366782Phase 1
8Safety and Tolerability Study to Evaluate MEDI-534 in Children 6 to < 24 Months of AgeCompletedNCT00493285Phase 1
9Safety of and Immune Response to Recombinant Live Attenuated Parainfluenza Type 3 Virus Vaccine in Healthy Infants and ChildrenCompletedNCT01021397Phase 1
10Safety of and Immune Response to a Human Parainfluenza Virus Vaccine (rHPIV3cp45) in Healthy InfantsCompletedNCT00308412Phase 1
11Study to Evaluate MEDI-534 in Healthy AdultsCompletedNCT00111878Phase 1
12Safety of and Immune Response to Recombinant Live-Attenuated Parainfluenza Type 1 Virus VaccineCompletedNCT00641017Phase 1
13T-Lymphocytes for Prevention or Treatment of Viral Infections Following Hematopoietic Stem Cell TransplantationRecruitingNCT03180216Phase 1
14A Study to Assess the Safety of Live Intranasal Sendai Virus Vaccine in Children and ToddlersRecruitingNCT00186927Phase 1
15Collection and Testing of Respiratory SamplesCompletedNCT01302418

Search NIH Clinical Center for Parainfluenza Virus Type 3

Genetic Tests for Parainfluenza Virus Type 3

About this section

Anatomical Context for Parainfluenza Virus Type 3

About this section

MalaCards organs/tissues related to Parainfluenza Virus Type 3:

36
Lung, T cells, Testes, Monocytes, Bone marrow, Liver, Bone

Publications for Parainfluenza Virus Type 3

About this section

Articles related to Parainfluenza Virus Type 3:

(show top 50)    (show all 277)
idTitleAuthorsYear
1
Inclusion Body Fusion of Human Parainfluenza Virus Type 3 Regulated by Acetylated I+-Tubulin Enhances Viral Replication. (27881643)
2017
2
A parainfluenza virus type 3 outbreak at a residential aged care facility: The role of microbiologic testing in early identification and antimicrobial stewardship. (27665033)
2016
3
Rapid detection of novel caprine parainfluenza virus type 3 (CPIV3) using a TaqMan-based RT-qPCR. (27448824)
2016
4
Viral Protein Requirements for Assembly and Release of Human Parainfluenza Virus Type 3 Virus-Like Particles. (26960133)
2016
5
Pathogenicity and horizontal transmission studies of caprine parainfluenza virus type 3 JS2013 strain in goats. (27374058)
2016
6
Identification of Interferon-Stimulated Gene Proteins That Inhibit Human Parainfluenza Virus Type 3. (27707917)
2016
7
A molecular epidemiological study of human parainfluenza virus type 3 at a tertiary university hospital during 2013-2015 in Catalonia, Spain. (27524509)
2016
8
Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study. (26204825)
2015
9
Mutations in the DI-DII Linker of Human Parainfluenza Virus Type 3 Fusion Protein Result in Diminished Fusion Activity. (26305905)
2015
10
Amino acid substitutions contributing to I+2,6-sialic acid linkage binding specificity of human parainfluenza virus type 3 hemagglutinin-neuraminidase. (25871520)
2015
11
Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN). (26364554)
2015
12
The aberrant gene-end transcription signal of the matrix M gene of human parainfluenza virus type 3 downregulates fusion F protein expression and the F-specific antibody response in vivo. (25589643)
2015
13
Identification of three antigen epitopes on the nucleocapsid protein of the genotype C of bovine parainfluenza virus type 3. (25960335)
2015
14
Development and evaluation of two truncated recombinant NP antigen-based indirect ELISAs for detection of bovine parainfluenza virus type 3 antibodies in cattle. (26031225)
2015
15
Human parainfluenza virus type 3 (HPIV3) induces production of IFNI^ and RANTES in human nasal epithelial cells (HNECs). (25722655)
2015
16
Interaction of Human Parainfluenza Virus Type 3 Nucleoprotein with Matrix Protein Mediates Internal Viral Protein Assembly. (26656716)
2015
17
Infection of the upper respiratory tract of hamsters by the bovine parainfluenza virus type 3 BN-1 strain expressing enhanced green fluorescent protein. (25543964)
2015
18
Parainfluenza virus type 3 Ab in allogeneic hematopoietic cell transplant recipients: factors influencing post-transplant Ab titers and associated outcomes. (24978141)
2014
19
Complete genome sequence of the first isolate of genotype C bovine parainfluenza virus type 3 in Japan. (25428970)
2014
20
Wheat germ cell-free system-based production of hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3 for generation and characterization of monoclonal antibody. (24860558)
2014
21
A leucine residue in the C terminus of human parainfluenza virus type 3 matrix protein is essential for efficient virus-like particle and virion release. (25187547)
2014
22
Phosphoprotein of human parainfluenza virus type 3 blocks autophagosome-lysosome fusion to increase virus production. (24832451)
2014
23
Molecular evolution of the haemagglutinin-neuraminidase gene in human parainfluenza virus type 3 isolates from children with acute respiratory illness in Yamagata prefecture, Japan. (24464692)
2014
24
A novel parainfluenza virus type 3 (PIV3) identified from goat herds with respiratory diseases in eastern China. (25236986)
2014
25
Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection. (24478424)
2014
26
Pathogenesis of a genotype C strain of bovine parainfluenza virus type 3 infection in albino guinea pigs. (24681303)
2014
27
Influence of antigen insertion site and vector dose on immunogenicity and protective capacity in Sendai virus-based human parainfluenza virus type 3 vaccines. (23514887)
2013
28
Complete Genome Sequences of Bovine Parainfluenza Virus Type 3 Strain BN-1 and Vaccine Strain BN-CE. (23469358)
2013
29
Human parainfluenza virus type 3 in wild nonhuman primates, Zambia. (23968816)
2013
30
Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3. (24324462)
2013
31
Prevalence of antibodies against Parainfluenza virus type 3, Respiratory syncitial virus and bovine Herpesvirus type 1 in sheep from Northern Prefectures of Japan. (24166480)
2013
32
Deletion of the D domain of the human parainfluenza virus type 3 (HPIV3) PD protein results in decreased viral RNA synthesis and beta interferon (IFN-I^) expression. (23686695)
2013
33
Parainfluenza virus type 3 outbreak in a neonatal nursery. (22511200)
2013
34
Role of N-linked glycosylation of the human parainfluenza virus type 3 hemagglutinin-neuraminidase protein. (23562646)
2013
35
An amino acid of human parainfluenza virus type 3 nucleoprotein is critical for template function and cytoplasmic inclusion body formation. (24027324)
2013
36
Molecular characterization of a Korean bovine parainfluenza virus type 3 isolate. (23140940)
2013
37
Seasonal patterns of respiratory syncytial virus, influenza A virus, human metapneumovirus, and parainfluenza virus type 3 infections on the basis of virus isolation data between 2004 and 2011 in Yamagata, Japan. (23514911)
2013
38
Antiviral activity of mycosynthesized silver nanoparticles against herpes simplex virus and human parainfluenza virus type 3. (24235828)
2013
39
Isolation and characterization of bovine parainfluenza virus type 3 from water buffaloes (Bubalus bubalis) in Argentina. (22716217)
2012
40
Molecular characterization and phylogenetic analysis of human parainfluenza virus type 3 isolated from Saudi Arabia. (22711360)
2012
41
Studies on the pathogenesis of a Chinese strain of bovine parainfluenza virus type 3 infection in Balb/c mice. (22391217)
2012
42
Phylogenetic analysis of the bovine parainfluenza virus type 3 from cattle herds revealing the existence of a genotype A strain in China. (22923090)
2012
43
Mutations within the human parainfluenza virus type 3 (HPIV 3) C protein affect viral replication and host interferon induction. (22634035)
2012
44
Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children. (22178099)
2012
45
Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. (21926667)
2012
46
Impact of parainfluenza virus type 3 infection on engraftment after hematopoietic SCT. (21478915)
2012
47
Sulfatide negatively regulates the fusion process of human parainfluenza virus type 3. (22821828)
2012
48
Human parainfluenza virus type 3 (HPIV 3) viral community-acquired pneumonia (CAP) mimicking swine influenza (H1N1) during the swine flu pandemic. (20888645)
2011
49
Analysis of nucleotides 13-96 of the human parainfluenza virus type 3 antigenomic promoter reveals positive- and negative-acting replication elements. (21880340)
2011
50
Human parainfluenza virus type 3 (HPIV 3) community-acquired pneumonia (CAP) mimicking pertussis in an adult: the diagnostic importance of hoarseness and monocytosis. (20888644)
2011

Variations for Parainfluenza Virus Type 3

About this section

Expression for genes affiliated with Parainfluenza Virus Type 3

About this section
Search GEO for disease gene expression data for Parainfluenza Virus Type 3.

Pathways for genes affiliated with Parainfluenza Virus Type 3

About this section

Pathways related to Parainfluenza Virus Type 3 according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
19.6CIITA, IFNB1

GO Terms for genes affiliated with Parainfluenza Virus Type 3

About this section

Biological processes related to Parainfluenza Virus Type 3 according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1cellular response to exogenous dsRNAGO:007136010.1CIITA, IFNB1
2cellular response to interferon-gammaGO:00713469.4CIITA, GAPDH

Sources for Parainfluenza Virus Type 3

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet